Volume 67, Issue 3 pp. 447-450
Experimental Cancer

Clonality and stability of the p53 gene in human astrocytic tumor cells: Quantitative analysis of p53 gene mutations by yeast functional assay

Mitsuhiro Tada

Corresponding Author

Mitsuhiro Tada

Department of Neurosurgery, University of Hokkaido School of Medicine, Sapporo, Japan

Department of Neurosurgery, University of Hokkaido School of Medicine, North-15 West-7, Kita-Ku, Sapporo 060, Japan. Fax: 0(81)11-706-7878; e-mail: m―[email protected]Search for more papers by this author
Richard D. Iggo

Richard D. Iggo

Oncogene Group, Swiss Institute for Experimental Cancer Research (ISREC), Epalinges, Switzerland

Search for more papers by this author
Nobuaki Ishii

Nobuaki Ishii

Department of Neurosurgery, University of Hokkaido School of Medicine, Sapporo, Japan

Search for more papers by this author
Yumiko Shinohe

Yumiko Shinohe

Department of Neurosurgery, University of Hokkaido School of Medicine, Sapporo, Japan

Search for more papers by this author
Shirou Sakuma

Shirou Sakuma

Department of Neurosurgery, University of Hokkaido School of Medicine, Sapporo, Japan

Search for more papers by this author
Anne Estreicher

Anne Estreicher

Oncogene Group, Swiss Institute for Experimental Cancer Research (ISREC), Epalinges, Switzerland

Search for more papers by this author
Yutaka Sawamura

Yutaka Sawamura

Department of Neurosurgery, University of Hokkaido School of Medicine, Sapporo, Japan

Search for more papers by this author
Hiroshi Abe

Hiroshi Abe

Department of Neurosurgery, University of Hokkaido School of Medicine, Sapporo, Japan

Search for more papers by this author

Abstract

Mutation of the p53 gene is found in about one third of astrocytic brain tumors, and expansion of tumor cell clones containing mutant p53 has been implicated in astrocytic tumor progression. However, admixture of normal cells in astrocytic tumor specimens limits the power of traditional studies of tumor cell clonality. To address this problem we have employed a yeast p53 functional assay that scores the content of mutant p53 alleles in tumors and cell lines quantitatively. We have analyzed 17 cases where matching tumor material and derived cell lines were available. The yeast assay gave >20% red (i.e., mutant p53-containing) yeast colonies in 7 out of 17 cases. One case had no mutations in the primary tumor but gave 76% red colonies in a recurrence, clearly demonstrating tumor overgrowth by a mutant clone. During early passages of cultured tumor cells, mutant p53 content increased rapidly with passage due to outgrowth of mutant clones from a heterogeneous starting population. In addition, de novo p53 mutations appeared during culture in 2 cases. This indicates that there is stronger selective pressure for mutation during the establishment of cell lines in vitro than during tumor growth in vivo. Our results demonstrate the utility of the p53 functional assay for studies of clonality and support the hypothesis of clonal progression of brain tumors in vivo. © 1996 Wiley-Liss, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.